Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias

[1]  A. Das,et al.  A conditionally replicating HIV-based vector that stably expresses an antiviral shRNA against HIV-1 replication. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  M. Lenardo,et al.  The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[3]  B. Cullen.  Role and Mechanism of Action of the APOBEC3 Family of Antiretroviral Resistance Factors , 2006, Journal of Virology.

[4]  J. Bell,et al.  Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.

[5]  L. de Leval,et al.  Bovine herpesvirus 4 induces apoptosis of human carcinoma cell lines in vitro and in vivo. , 2005, Cancer research.

[6]  P. Fisher,et al.  Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. , 2005, Cancer research.

[7]  P. Fisher,et al.  Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Wainberg,et al.  Regulation of Human Immunodeficiency Virus Type 1 Gene Expression by Clade-Specific Tat Proteins , 2005, Journal of Virology.

[9]  B. Berkhout,et al.  Construction of a minimal HIV-1 variant that selectively replicates in leukemic derived T-cell lines: towards a new virotherapy approach. , 2005, Cancer research.

[10]  J. Nemunaitis,et al.  Oncolytic viral therapies , 2004, Cancer Gene Therapy.

[11]  A. Das,et al.  Viral Evolution as a Tool to Improve the Tetracycline-regulated Gene Expression System* , 2004, Journal of Biological Chemistry.

[12]  V. Bond,et al.  Extracellular Nef Protein Targets CD4+ T Cells for Apoptosis by Interacting with CXCR4 Surface Receptors , 2004, Journal of Virology.

[13]  A. Das,et al.  A conditionally replicating virus as a novel approach toward an HIV vaccine. , 2004, Methods in enzymology.

[14]  A. Badley,et al.  Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. , 2003, The Journal of clinical investigation.

[15]  J. Nemunaitis,et al.  Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients , 2003, Cancer Gene Therapy.

[16]  A. Das,et al.  Conditional virus replication as an approach to a safe live attenuated human immunodeficiency virus vaccine. , 2002, Journal of neurovirology.

[17]  M. Emerman,et al.  Evidence for a cytopathogenicity determinant in HIV-1 Vpr , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Ben Berkhout,et al.  Efficient Human Immunodeficiency Virus Replication Requires a Fine-Tuned Level of Transcription , 2002, Journal of Virology.

[19]  C. Ring.  Cytolytic viruses as potential anti-cancer agents. , 2002, The Journal of general virology.

[20]  C. A. Derdeyn,et al.  Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles. , 2001, Human gene therapy.

[21]  J. Zaunders,et al.  An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[22]  A. Braithwaite,et al.  Does the Antitumor Adenovirus ONYX-015/dl1520 Selectively Target Cells Defective in the p53 Pathway? , 2001, Journal of Virology.

[23]  B. Berkhout,et al.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Berkhout,et al.  Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect. , 2001, Virology.

[25]  B. Berkhout,et al.  Strict Control of Human Immunodeficiency Virus Type 1 Replication by a Genetic Switch: Tet for Tat , 2001, Journal of Virology.

[26]  F. Khuri,et al.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. , 2000, Cancer research.

[27]  J. Kaldor,et al.  Characterization of Three nef-Defective Human Immunodeficiency Virus Type 1 Strains Associated with Long-Term Nonprogression , 2000, Journal of Virology.

[28]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[29]  B. Berkhout,et al.  A Second-Site Mutation That Restores Replication of a Tat-Defective Human Immunodeficiency Virus , 1999, Journal of Virology.

[30]  B. Berkhout,et al.  Genetic Instability of Live, Attenuated Human Immunodeficiency Virus Type 1 Vaccine Strains , 1999, Journal of Virology.

[31]  A. Das,et al.  A Hairpin Structure in the R Region of the Human Immunodeficiency Virus Type 1 RNA Genome Is Instrumental in Polyadenylation Site Selection , 1999, Journal of Virology.

[32]  B. Berkhout,et al.  Determination of the minimal amount of Tat activity required for human immunodeficiency virus type 1 replication. , 1997, Virology.

[33]  C. Sorg,et al.  Electroporation efficiency in mammalian cells is increased by dimethyl sulfoxide (DMSO). , 1996, Nucleic acids research.

[34]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[35]  J. S. Sullivan,et al.  Genomic Structure of an Attenuated Quasi Species of HIV-1 from a Blood Transfusion Donor and Recipients , 1995, Science.

[36]  B. Berkhout,et al.  Evolution of a disrupted TAR RNA hairpin structure in the HIV‐1 virus. , 1994, The EMBO journal.

[37]  R. Desrosiers,et al.  Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. , 1994, AIDS research and human retroviruses.

[38]  R. Desrosiers,et al.  Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. , 1994, AIDS research and human retroviruses.

[39]  B. Berkhout,et al.  In vivo selection of randomly mutated retroviral genomes. , 1993, Nucleic acids research.

[40]  J. Goudsmit,et al.  Natural HIV-1 NEF accelerates virus replication in primary human lymphocytes. , 1992, Virology.

[41]  B. Berkhout,et al.  trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis , 1989, Journal of virology.

[42]  H. Morse,et al.  Defective virus is associated with induction of murine retrovirus-induced immunodeficiency syndrome. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Eric C. Holland,et al.  HIV-1 tat trans-activation requires the loop sequence within tar , 1988, Nature.

[44]  R. Warnke,et al.  Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. , 1984, Cancer research.

[45]  N. Auersperg.  LONG-TERM CULTIVATION OF HYPODIPLOID HUMAN TUMOR CELLS. , 1964, Journal of the National Cancer Institute.